← ANALYST RATINGS · TIPRANKS
Oric Pharmaceuticals (ORIC): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $23.11, the highest $27.00, the lowest $14.00. The average is +87.1% from the last price of $12.35.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.50 → $12.00−4.0% | Hold | −2.8% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.50−4.2% | Hold | −6.9% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $23.00 → $26.00+13.0% | Buy | +110.5% | Assigned | 14.10.26on TipRanks 07:15 | +3.6%next day +9.9% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.00 → $12.50−3.8% | Hold | +1.2% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 → $11.50−4.2% | Hold | −6.9% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 → $12.00−4.0% | Hold | −2.8% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $12.00−4.0% | Hold | −2.8% | Reiterated | 11.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 → $12.00+4.3% | Hold | −2.8% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $12.50+4.2% | Hold | +1.2% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 → $11.50−4.2% | Hold | −6.9% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $12.00−4.0% | Hold | −2.8% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $26.00 | Buy | +110.5% | Initiated | 23.09.26on TipRanks 06:15 | −0.5%next day −1.0% · 5 days +1.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.50 | Hold | +1.2% | Reiterated | 13.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.00 | Hold | +5.3% | Reiterated | 13.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 | Hold | −2.8% | Reiterated | 13.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 | Hold | −2.8% | Reiterated | 13.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 | Hold | +1.2% | Reiterated | 13.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 | Hold | +1.2% | Reiterated | 13.09.26on TipRanks 06:05 | — | |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $25.00 → $27.00+8.0% | Buy | +118.6% | Reiterated | 10.08.26on TipRanks 06:30 | +0.9%next day +1.1% · 5 days −1.7% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $23.00 | Buy | +86.2% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | +0.2%next day +3.8% · 5 days +4.9% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $25.00 | Buy | +102.4% | Reiterated | 04.08.26on TipRanks 10:34 | +25.3%next day −3.8% · 5 days +2.0% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $25.00 | Buy | +102.4% | Reiterated | 04.08.26on TipRanks 07:56 | +25.3%next day −3.8% · 5 days +2.0% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $14.00 | Buy | +13.4% | Reiterated | 04.08.26on TipRanks 07:56 | +25.3%next day −3.8% · 5 days +2.0% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $25.00 | Buy | +102.4% | Reiterated | 04.08.26on TipRanks 07:51 | +25.3%next day −3.8% · 5 days +2.0% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $22.00 | Buy | +78.1% | Assigned | 04.08.26on TipRanks 07:45 | +25.3%next day −3.8% · 5 days +2.0% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $18.00 | Buy | +45.7% | Reiterated | 03.08.26on TipRanks Aug 4 07:51 | −5.7%next day +25.3% · 5 days +26.5% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $15.00 | Buy | +21.5% | Reiterated | 02.06.26on TipRanks Jun 3 08:15 | −15.3%next day +3.6% · 5 days +8.0% | ↗ |
| Unknown Analyst | Wedbush | $17.00 | Buy | +37.7% | Initiated | 05.05.26on TipRanks May 9 10:07 | −1.4%next day −4.2% · 5 days −9.7% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $17.00 → $16.00−5.9% | Buy | +29.6% | Assigned | 05.05.26on TipRanks 06:40 | −1.4%next day −4.2% · 5 days −9.7% | ↗ |
| Unknown Analyst | Roth MKM | $15.00 | Buy | +21.5% | Reiterated | 08.12.25on TipRanks 10:05 | −4.1%next day −3.5% · 5 days −11.8% | ↗ |
| Unknown Analyst | Wolfe Research | — | Hold | — | Initiated | 17.11.25on TipRanks 16:40 | −0.5%next day −3.9% · 5 days −4.6% | ↗ |
| Kevin DeGeeter★★★★★★★★★★#705 · hits 38% · avg +19.0% | Ladenburg Thalmann & Co. | $15.00 | Buy | +21.5% | Reiterated | 14.11.25on TipRanks 14:51 | +0.5%next day −0.6% · 5 days −3.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Oric Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.78 at a price of $13.47 (+69.1%); now: $23.11 at $12.35 (+87.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 16 | 12 | 13 | 8 | 9 |
| Buy | 6 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.38 (from $-0.45 to $-0.33). Last quarter: $-0.38.
Best top-analyst consensus in the sector · Healthcare
About Oric Pharmaceuticals
- CEO: Jacob Chacko
- Employees: 111
- 240 East Grand Avenue, South San Francisco, CA, 94080, US
- www.oricpharma.com
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 39 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗